Following successful completion of a pilot phase, the BC-CfE Pharmacovigilance project became an ongoing initiative to ensure the safe use of antiretroviral therapy in BC. This was particularly important in preparation for the STOP HIV/AIDS program. The scaling up of HIV therapy across BC required evidence of safety and confidence that there would be no unintended harm to the population taking antiretrovirals.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
